In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinson’s cohort, to aid future research.
Through a recently announced partnership with TrialSpark, 23andMe has entered the clinical trials market – an area in which the direct-to-consumer genetic testing company feels it has the potential to grow.